Followers | 2770 |
Posts | 77901 |
Boards Moderated | 1 |
Alias Born | 05/10/2007 |
![](https://investorshub.advfn.com/uicon/100565.png?cb=1533604822)
Sunday, May 07, 2017 5:31:20 PM
--------------------------------------------------------------------------------
Okay. And just a last point on that is has something, since you called out the Regeneron partnership in the press release and on the call here, did something specifically progress forward in that development pathway over the last three months or since your last update?
--------------------------------------------------------------------------------
Amar Sawhney, Ocular Therapeutix, Inc. - President, CEO & Chairman [50]
--------------------------------------------------------------------------------
So it's hard for us to comment given that this is something that we have to collaboratively speak about. So we cannot make unilateral statements.
All I would say is that the relationship is progressing nicely. And they are continue to be very enthused about the progress that is being made and we have provided them with product candidates that they are in the process of testing and feel that that's going in the right direction.
Recent OCUL News
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/09/2024 11:30:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/07/2024 08:15:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 11:23:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:13:30 AM
- Ocular Therapeutix™ Reports Second Quarter 2024 Results • GlobeNewswire Inc. • 08/07/2024 11:10:00 AM
- Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 08:30:50 PM
- Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024 • GlobeNewswire Inc. • 07/31/2024 11:30:00 AM
- Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 10:41:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 10:40:11 PM
- Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/18/2024 08:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/17/2024 08:19:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/16/2024 08:22:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/15/2024 08:53:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/12/2024 08:20:42 PM
- Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting • GlobeNewswire Inc. • 07/10/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/09/2024 08:23:26 PM
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/08/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/17/2024 08:12:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 01:03:53 PM
- Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study • GlobeNewswire Inc. • 06/13/2024 08:05:00 PM
- Ocular Therapeutix® to Host Investor Day on June 13, 2024 • GlobeNewswire Inc. • 06/05/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:28:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:26:14 PM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM